Al M. J., Feenstra T. Brouwer W. B. (2004), ‘Decision makers’ views on health care objectives and budget constraints: results from a pilot study’, Health Policy, 70(1): 33–48.
Barbieri M., Hawkins N. Sculpher M. (2009), ‘Who does the numbers? The role of third-party technology assessment to inform health systems’ decision-making about the funding of health technologies’, Value Health, 12(2): 193–201.
Bryan S., Williams I. McIver S. (2007), ‘Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals’, Health Economics, 16(2): 179–193.
Buxton M. J. (2005), ‘How much are health-care systems prepared to pay to produce a QALY?’, European Journal of Health Economics, 6: 285–287.
Chalkidou K. (2009), ‘Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence’, The Commonwealth Fund Issue Brief, 59: 1–12.
Clement F. M., Harris A., Li J. J., Yong K., Lee K. M. Manns B. J. (2009), ‘Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada’, JAMA, 302(13): 1437–1443.
Dakin H. A., Devlin N. J. Odeyemi I. A. O. (2006), ‘“Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making’, Health Policy, 77: 352–367.
Department of Health (2002), Improvement, Expansion and Reform: The Next Three Years Priorities and Planning Framework 2003–2006 London: Department of Health (Crown Copyright).
Department of Health (2006a), The NHS in England: The Operating Framework for 2006/7, London: Crown Copyright.
Department of Health (2006b), The NHS in England: The Operating Framework for 2007/08, London: Crown Copyright.
Department of Health (2007), The NHS in England: The Operating Framework for 2008/09, London: Crown Copyright.
Devlin N. Parkin D. (2004), ‘Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis’, Health Economics, 13(5): 437–452.
European Medicines Agency (2011), ‘European Public Assessment Reports’, www.ema.europa.eu/ema [30 March 2011].
Henshall C., Oortwijn W., Stevens A., Granados A. Banta D. (1997), ‘Priority setting for health technology assessment – theoretical considerations and practical approaches – a paper produced by the priority setting subgroup of the EUR ASSESS project’, International Journal of Technology Assessment in Health Care, 13(2): 144–185.
Joint Formulary Committee (2010), British National Formulary, 60 ed, London: British Medical Association and Royal Pharmaceutical Society.
Kanavos P., Nicod E., van den Aardweg S. Pomedli S. (2010), ‘The impact of health technology assessments: an international comparison’, Euro Observer 12(4): 1–7.
Littlejohns P., Garner S., Doyle N., Macbeth F., Barnett D. Longson C. (2009), ‘10 years of NICE: still growing and still controversial’, Lancet Oncology, 10(4): 417–424.
Mason A. R. Drummond M. F. (2009), ‘Public funding of new cancer drugs: Is NICE getting nastier?’, European Journal of Cancer, 45(7): 1188–1192.
Menon D., Stafinski T. Stuart G. (2005), ‘Access to drugs for cancer: Does where you live matter?’, Canadian Journal of Public Health, 96(6): 454–458.
National Office for Statistics (2009), Key demographic and health indicators, 1976 onwards: Population Trends. ONS 1976-2008 data.
NICE (2009), Threshold Workshop Report. NICE.
O'Neill P. Devlin N. J. (2010), ‘An analysis of NICE's ‘restricted’ (or ‘optimized’) decisions’, Pharmacoeconomics, 28(11): 987–993.
OECD ed. (2005), Health Technologies and Decision Making, The OECD Health Project, OECD Publishing. Printed in France.
Owens D. K. (1998), ‘Interpretation of cost-effectiveness analyses’, JGIM, 13: 716–717.
Packer C., Simpson S. Stevens A., EuroScan: the European Information Network on New and Changing Health Technologies. (2006), ‘International diffusion of new health technologies: a ten-country analysis of six health technologies’, International Journal of Technology Assessment in Health Care, 22(4): 419–428.
Raftery J. (2006), ‘Review of NICE's recommendations, 1999–2005’, BMJ, 332(7552): 1266–1268.
Ross J. (1995), ‘The use of economic evaluation in health care: Australian decision makers’ perceptions’, Health Policy, 31(2): 103–110.
Sorenson C., Drummond M., Kanavos P. (2008). Ensuring value for Money in Health Care: the role of HTA in the European Union. Cornwall: World Health Organisation, on behalf of the European Observatory on Health Systems and Policies.
Summerhayes M. Catchpole P. (2006), ‘Has NICE been nice to cancer?’, European Journal of Cancer, 42(17): 2881–2886.
Velasco Garrido M. Busse R. (2005), Health Technology Assessment – An Introduction on Objectives, Role of Evidence, and Structure in Europe, Brussels: European Observatory on Health Systems and Policies.
Vuorenkoski L., Toiviainen H. Hemminki E. (2008), ‘Decision-making in priority setting for medicines – a review of empirical studies’, Health Policy, 86(1): 1–9.